Halaven

This page shows the latest Halaven news and features for those working in and with pharma, biotech and healthcare.

NICE set to reject wider use of Eisai’s Halaven

NICE set to reject wider use of Eisai’ s Halaven. Issues draft guidance recommending against second-line use in breast cancer. ... Eisai’s Halaven (eribulin) should not be funded by the NHS for earlier use in breast cancer patients, according to

Latest news

NICE backs Eisai's Halaven for breast cancer

NICE backs Eisai's Halaven for breast cancer. Reverses 2012 rejection due to new data and patient access discount. ... NICE has given a green light to Eisai's third-line breast cancer therapy Halaven, reversing its 2012 rejection of the drug.
Lilly closes on first approval for sarcoma drug Lartruvo

If approved, the drug will join other new therapies for STS, including Johnson &Johnson's chemotherapy agent Yondelis (trabectedin) and Eisai's Halaven (eribulin mesylate), both of which have been approved
Eisai gets green light for Lenvima in kidney cancer

Earlier this month, Eisai won EU approval for its Halaven (eribulin mesylate) product as a second-line treatment for adults with inoperable advanced liposarcoma, its second indication after metastatic breast cancer.
Oncology directions

Halaven (eribulin).
Disappointment for pharma with new Cancer Drugs Fund list

While Bayer has seen reprieve the rest were not so lucky, with Eisai's breast cancer drug Halaven (eribulin), Lilly's lung cancer therapy Alimta (pemetrexed) and Roche's blockbuster

More from news
Approximately 8 fully matching, plus 25 partially matching documents found.

Latest Intelligence

Eisai: Bucking the trend with R&D growth

The company is also still very much in launch mode with its first cancer drug Halaven, which has been brought to most of the major European markets. “ ... Halaven's unique position as the only drug demonstrating overall survival benefit in patients who
Country report: The healthcare market in Japan

The approval of Halaven (eribulin, Eisai) for progressive breast cancer in the US in late 2010, and in Europe and Japan in early 2011, signalled the impact of a growing number

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Healthcare PR Director: £100, 000 – £120, 000 benefits

Home based, Principal Medical Writer, Medical Communications: Excellent package

Senior Project Manager - Medical Writing: Great salary and bebefits

Account Manager, Medical Communications and Marketing: £30, 000 – £40, 000 benefits and bonus

Delivery Manager/ Head of Delivery – Executive Search: Neg

Client Services Director – Healthcare Advertising - London: Neg

Client Services Director - Med Comms: Great salary and bebefits

Senior Account Manager: Competitive salary commensurate with experience

Scientific Communications Director - Oncology – In House Pharma ...: Neg

Business Unit Head, Medical Communications, London: Excellent package

Account Manager: £40, 000 - £45, 000 benefits

Principal Medical Writer / Editorial Director – Medical Communic...: £60, 000 - £80, 000

Home based, Chief Medical Writer, Medical Communications: Excellent package

Home based, Senior Medical Writer, Medical Communications: Excellent package

Senior Medical Writer, Healthcare Advertising Agency: £45, 000 – £50, 000

Head of Market Access - International - Based Cambridge: Excellent Basic, Bonus and Flex Benefits

Home based, Editorial Team Leader, Medical Communications: Excellent package

Strategic Planner, Healthcare Advertising: £47, 000 – £53, 000

Account Director, Consumer Healthcare PR, Global PR agency: £50, 000 – £58, 000

Account Director, Medical Communications: C£50 – 65, 000 benefits and bonus

Editorial Director – Medical Education (MedComms): Neg

Subscribe to our email news alerts

PMHub

Add my company

Ashley Communications

Ashley Communications is a bespoke, independent medical communications consultancy consistently providing a unique director-delivered client service tailored to individual client...

Latest intelligence

Developing advocacy in the pharmaceutical industry.: The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?: Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?: The modern approach to B2B sales is data-driven, and enabled by digital tools....